Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib
- 11 August 2016
- journal article
- Published by Wiley in The Journal of Dermatology
- Vol. 44 (3), e15-e16
- https://doi.org/10.1111/1346-8138.13534
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Cutaneous toxicities associated with vemurafenib therapy in 107 patients withBRAFV600E mutation-positive metastatic melanoma, including recognition and management of rare presentationsBritish Journal of Dermatology, 2015
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety studyThe Lancet Oncology, 2014
- Acneiform eruptions associated with vemurafenibJournal of the American Academy of Dermatology, 2013
- Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer AgentsArchives of Dermatology, 2011
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010